Celltrion signs up to support Queen’s oral biosimilar copy of J&J’s Stelara, gets first negotiation rights

Queen is medical science. Rani Therapeutics has secured supplies of ustekinumab for an oral drug delivery program, partnering with Celltrion to access materials for the development of a biosimilar rival to Johnson & Johnson’s Stelara. The deal gives Celltrion the right of first negotiation on the oral ustekinumab biosimilar program.